Juan P Casas

Author PubWeight™ 141.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011 13.25
2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011 13.23
3 A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010 8.48
4 Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 2013 7.44
5 CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011 5.93
6 Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011 5.56
7 Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009 4.61
8 Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2010 4.42
9 Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet 2012 3.40
10 Estimation of bias in nongenetic observational studies using "mendelian triangulation". Ann Epidemiol 2006 2.57
11 Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet 2012 2.53
12 Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011 2.35
13 Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 2013 2.18
14 Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet 2010 2.15
15 Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2008 2.14
16 Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012 1.96
17 Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med 2008 1.95
18 Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst 2012 1.83
19 Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J 2011 1.73
20 Statins for all by the age of 50 years? Lancet 2012 1.69
21 Tackling non-communicable diseases in low- and middle-income countries: is the evidence from high-income countries all we need? PLoS Med 2013 1.67
22 Congestive heart failure in Latin America: the next epidemic. Am Heart J 2004 1.58
23 Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One 2013 1.56
24 Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012 1.52
25 Noncommunicable diseases and injuries in Latin America and the Caribbean: time for action. PLoS Med 2006 1.49
26 Bayesian meta-analysis of genetic association studies with different sets of markers. Am J Hum Genet 2008 1.44
27 Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009 1.43
28 Could NICE guidance on the choice of blood pressure lowering drugs be simplified? BMJ 2012 1.41
29 Genetics of ischaemic stroke among persons of non-European descent: a meta-analysis of eight genes involving approximately 32,500 individuals. PLoS Med 2007 1.38
30 Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med 2014 1.31
31 Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies. Eur Heart J 2012 1.30
32 Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals. Atherosclerosis 2010 1.27
33 Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J 2008 1.22
34 Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation 2009 1.20
35 Integrated associations of genotypes with multiple blood biomarkers linked to coronary heart disease risk. Hum Mol Genet 2009 1.17
36 Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction. Circ Cardiovasc Genet 2010 1.16
37 Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet 2013 1.15
38 Complement factor H genetic variant and age-related macular degeneration: effect size, modifiers and relationship to disease subtype. Int J Epidemiol 2012 1.12
39 Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J 2012 1.12
40 Does high C-reactive protein concentration increase atherosclerosis? The Whitehall II Study. PLoS One 2008 1.09
41 C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus. Atherosclerosis 2004 1.07
42 UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol 2006 1.06
43 Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case-control study. Hypertension 2004 1.04
44 Area-level deprivation and overall and cause-specific mortality: 12 years' observation on British women and systematic review of prospective studies. PLoS One 2013 1.04
45 Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 2013 1.03
46 Population genomics of cardiometabolic traits: design of the University College London-London School of Hygiene and Tropical Medicine-Edinburgh-Bristol (UCLEB) Consortium. PLoS One 2013 1.02
47 Multilocus Bayesian meta-analysis of gene-disease associations. Am J Hum Genet 2009 1.00
48 (6R)-5,6,7,8-tetrahydro-L-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. Arterioscler Thromb Vasc Biol 2007 0.99
49 Social capital, mortality, cardiovascular events and cancer: a systematic review of prospective studies. Int J Epidemiol 2014 0.98
50 C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem 2008 0.97
51 Modelling the association of disability according to the WHO International Classification of Functioning, Disability and Health (ICF) with mortality in the British Women's Heart and Health Study. J Epidemiol Community Health 2011 0.96
52 Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis. Int J Epidemiol 2012 0.95
53 Predictors of patterns of change in health-related quality of life in older women over 7 years: evidence from a prospective cohort study. Age Ageing 2013 0.94
54 Missing data methods in Mendelian randomization studies with multiple instruments. Am J Epidemiol 2011 0.93
55 Using waist circumference as a screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehabil 2003 0.91
56 Linking observational and genetic approaches to determine the role of C-reactive protein in heart disease risk. Eur Heart J 2006 0.91
57 Frequency of eNOS polymorphisms in the Colombian general population. BMC Genet 2010 0.91
58 Angiotensin-converting enzyme I/D polymorphism and preeclampsia risk: evidence of small-study bias. PLoS Med 2006 0.91
59 A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry 2013 0.87
60 Gene-centric analysis identifies variants associated with interleukin-6 levels and shared pathways with other inflammation markers. Circ Cardiovasc Genet 2013 0.86
61 Regional pathologies and globalization of clinical trials: has the time for regional trials arrived? Circulation 2003 0.85
62 A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health Aff (Millwood) 2013 0.84
63 Endothelial nitric oxide synthase gene polymorphism (Glu298Asp) and development of pre-eclampsia: a case-control study and a meta-analysis. BMC Pregnancy Childbirth 2006 0.83
64 Plasma concentrations of asymmetric dimethylarginine (ADMA) in Colombian women with pre-eclampsia. JAMA 2004 0.82
65 Effect of changes in moderate or vigorous physical activity on changes in health-related quality of life of elderly British women over seven years. Qual Life Res 2012 0.81
66 The role of infection in cardiovascular disease: more support but many questions remain. Eur Heart J 2007 0.81
67 Inflammation, coagulation and risk of locomotor disability in elderly women: findings from the British Women's Heart and Health Study. Eur J Epidemiol 2012 0.79
68 CHARITY: Chagas cardiomyopathy bisoprolol intervention study: a randomized double-blind placebo force-titration controlled study with Bisoprolol in patients with chronic heart failure secondary to Chagas cardiomyopathy [NCT00323973]. Trials 2006 0.78
69 Alcohol consumption and cognitive performance: a Mendelian randomization study. Addiction 2014 0.78
70 Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease? Eur Heart J 2012 0.77
71 Oxygen therapy in acute myocardial infarction – good or bad? Cochrane Database Syst Rev 2013 0.76
72 Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. J Am Coll Cardiol 2013 0.76
73 Putting genomics into practice. BMJ 2011 0.75
74 Ximelagatran or warfarin in atrial fibrillation? Lancet 2004 0.75